NMRA
Neumora Therapeutics, Inc.
Price Chart
Latest Quote
$1.51
-0.02 (-0.98%)
Current Price
| Previous Close | $1.53 |
| Open | $1.49 |
| Day High | $1.60 |
| Day Low | $1.49 |
| Volume | 513,200 |
Stock Information
| Shares Outstanding | 185.28M |
| Total Debt | $53.37M |
| Cash Equivalents | $147.07M |
| Net Income | $-222.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $298.31M |
| EPS (TTM) | $-1.39 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $204.61M |
| Income | $-222.39M |
| Book/sh | $0.39 |
| Cash/sh | $0.79 |
| Employees | 92 |
Financial Ratios
| Quick Ratio | 4.88 |
| Current Ratio | 5.09 |
| Debt/Eq | 75.51 |
Returns & Margins
| ROA | -66.39% |
| ROE | -148.74% |
Ownership
| Insider Ownership | 23.60% |
| Institutional Ownership | 57.93% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.08 |
| P/B | 4.15 |
Analyst Data
| Recommendation | buy |
| Target Price | $6.53 |
Technical Indicators
| SMA20 | $1.66 |
| SMA50 | $1.91 |
| SMA200 | $2.19 |
| RSI | 46.62 |
| ATR | 0.2329 |
| Shares Float | 113.21M |
| Short Float | 5.20% |
| Short Ratio | 3.99 |
| Volatility | 2.76 |
| Rel Volume | 0.59 |
Performance History
| Week | +75.96% |
| Month | -12.97% |
| Quarter | -34.82% |
| 6 Months | -6.40% |
| YTD | -3.01% |
| Year | +104.83% |
| 10 Years | -90.53% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $1.61 | 2,045,885 |
| 2026-06-22 | $1.53 | 1,529,500 |
| 2026-06-18 | $1.51 | 2,200,600 |
| 2026-06-17 | $1.53 | 5,352,200 |
| 2026-06-16 | $1.56 | 28,535,200 |
| 2026-06-15 | $0.92 | 17,741,700 |
| 2026-06-12 | $1.78 | 719,300 |
| 2026-06-11 | $1.78 | 1,148,300 |
| 2026-06-10 | $1.60 | 671,400 |
| 2026-06-09 | $1.65 | 785,200 |
| 2026-06-08 | $1.62 | 601,000 |
| 2026-06-05 | $1.63 | 864,600 |
| 2026-06-04 | $1.75 | 704,200 |
| 2026-06-03 | $1.74 | 647,400 |
| 2026-06-02 | $1.75 | 840,500 |
| 2026-06-01 | $1.82 | 803,200 |
| 2026-05-29 | $1.85 | 892,400 |
| 2026-05-28 | $1.88 | 1,284,500 |
| 2026-05-27 | $1.86 | 719,900 |
| 2026-05-26 | $1.84 | 1,292,900 |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
đ° Latest News
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprantâs Upcoming Depression Data
Insider Monkey âĸ 2026-06-17T15:17:12Z
Three pivotal MDD trial failures for Neumora lead to staffing cuts
Clinical Trials Arena âĸ 2026-06-16T15:58:51Z
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
Zacks âĸ 2026-06-16T14:13:00Z
Neumora depression drug fails; EnGene to cut 50% of staff
BioPharma Dive âĸ 2026-06-16T09:08:00Z
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires âĸ 2026-06-15T19:46:51ZSector Update: Healthcare Stocks Softer Monday Afternoon
MT Newswires âĸ 2026-06-15T17:50:10ZNMRA Stock On Track For Worst Day In 1.5 Years â Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
Stocktwits âĸ 2026-06-15T17:21:16Z
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA)
InvestorsHub âĸ 2026-06-15T13:28:53Z
SoftBank Just Dumped Circle Stock. Donât Panic and Keep Adding CRCL Here.
Barchart âĸ 2026-05-19T19:49:51Z
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode
Insider Monkey âĸ 2026-04-12T21:45:36Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $3,219,000 | - | - | - |
| Total Expenses | $241,156,000 | $263,464,000 | $252,098,000 | $135,870,000 |
| Other Income Expense | $-767,000 | $-78,000 | $-170,000 | $405,000 |
| Other Non Operating Income Expenses | $-767,000 | $-78,000 | $-170,000 | $405,000 |
| Net Non Operating Interest Income Expense | $5,125,000 | $19,933,000 | $16,611,000 | $4,561,000 |
| Interest Expense Non Operating | $3,219,000 | - | - | - |
| Operating Expense | $241,156,000 | $263,464,000 | $252,098,000 | $135,870,000 |
| General And Administrative Expense | $60,091,000 | $62,537,000 | $45,475,000 | $31,121,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Net Interest Income | $5,125,000 | $19,933,000 | $16,611,000 | $4,561,000 |
| Interest Income | $8,344,000 | $19,933,000 | $16,611,000 | $4,561,000 |
| Normalized Income | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Net Income From Continuing And Discontinued Operation | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Total Operating Income As Reported | $-241,156,000 | $-263,464,000 | $-252,098,000 | $-135,870,000 |
| Net Income Common Stockholders | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Net Income | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Net Income Including Noncontrolling Interests | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Net Income Continuous Operations | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Pretax Income | $-236,798,000 | $-243,609,000 | $-235,657,000 | $-130,904,000 |
| Interest Income Non Operating | $8,344,000 | $19,933,000 | $16,611,000 | $4,561,000 |
| Operating Income | $-241,156,000 | $-263,464,000 | $-252,098,000 | $-135,870,000 |
| Per Share | ||||
| Diluted EPS | $-1.45 | $-1.53 | $-3.63 | $-0.86 |
| Basic EPS | $-1.45 | $-1.53 | $-3.63 | $-0.86 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-233,371,000 | $-262,833,000 | $-251,430,000 | $-135,276,000 |
| Reconciled Depreciation | $208,000 | $631,000 | $668,000 | $594,000 |
| EBITDA (Bullshit earnings) | $-233,371,000 | $-262,833,000 | $-251,430,000 | $-135,276,000 |
| EBIT | $-233,579,000 | $-263,464,000 | $-252,098,000 | $-135,870,000 |
| Diluted Average Shares | $163,391,000 | $159,377,000 | $65,021,000 | $151,949,096 |
| Basic Average Shares | $163,391,000 | $159,377,000 | $65,021,000 | $151,949,096 |
| Diluted NI Availto Com Stockholders | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Tax Provision | $130,000 | $178,000 | $268,000 | $0 |
| Research And Development | $181,065,000 | $200,927,000 | $206,623,000 | $104,749,000 |
| Selling General And Administration | $60,091,000 | $62,537,000 | $45,475,000 | $31,121,000 |
| Other Gand A | $60,091,000 | $62,537,000 | $45,475,000 | $31,121,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $103,871,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Total Assets | $191,047,000 | $316,972,000 | $496,195,000 | $426,234,000 |
| Total Non Current Assets | $510,000 | $2,917,000 | $17,916,000 | $38,279,000 |
| Other Non Current Assets | $53,000 | - | $1,213,000 | $4,126,000 |
| Current Assets | $190,537,000 | $314,055,000 | $478,279,000 | $387,955,000 |
| Other Current Assets | $8,007,000 | $5,264,000 | $24,297,000 | - |
| Restricted Cash | $0 | $1,213,000 | $0 | $50,000 |
| Cash Cash Equivalents And Short Term Investments | $182,530,000 | $307,578,000 | $453,982,000 | $371,884,000 |
| Cash And Cash Equivalents | $182,530,000 | $142,148,000 | $374,038,000 | $240,943,000 |
| Prepaid Assets | - | - | $23,358,000 | $15,102,000 |
| Receivables | - | - | $939,000 | $919,000 |
| Other Receivables | - | - | $939,000 | $919,000 |
| Non Current Prepaid Assets | - | - | - | $0 |
| Non Current Deferred Assets | - | - | - | $2,912,000 |
| Debt | ||||
| Total Debt | $55,009,000 | $1,853,000 | $5,231,000 | $8,442,000 |
| Long Term Debt And Capital Lease Obligation | $54,725,000 | $0 | $1,853,000 | $5,072,000 |
| Long Term Debt | $54,532,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $284,000 | $1,853,000 | $3,378,000 | $3,370,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $87,176,000 | $29,908,000 | $27,119,000 | $873,084,000 |
| Total Non Current Liabilities Net Minority Interest | $54,725,000 | $22,000 | $2,008,000 | $849,387,000 |
| Current Liabilities | $32,451,000 | $29,886,000 | $25,111,000 | $23,697,000 |
| Payables And Accrued Expenses | $20,673,000 | $17,925,000 | $11,583,000 | $10,283,000 |
| Payables | $3,379,000 | $3,307,000 | $337,000 | $7,147,000 |
| Accounts Payable | $3,379,000 | $3,307,000 | $337,000 | $7,147,000 |
| Other Non Current Liabilities | - | $22,000 | $155,000 | $628,000 |
| Other Current Liabilities | - | $133,000 | $139,000 | $1,644,000 |
| Equity | ||||
| Common Stock Equity | $103,871,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Total Equity Gross Minority Interest | $103,871,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Stockholders Equity | $103,871,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $62,000 | $-76,000 | $-774,000 |
| Retained Earnings | $-1,184,149,000 | $-947,221,000 | $-703,434,000 | $-467,509,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $0 | $843,687,000 |
| Other Equity Adjustments | - | $62,000 | $-76,000 | $-774,000 |
| Other | ||||
| Ordinary Shares Number | $174,260,336 | $161,709,907 | $158,832,000 | $151,949,096 |
| Share Issued | $174,260,336 | $161,709,907 | $158,832,000 | $151,949,096 |
| Tangible Book Value | $103,871,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Invested Capital | $158,403,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Working Capital | $158,086,000 | $284,169,000 | $453,168,000 | $364,258,000 |
| Capital Lease Obligations | $477,000 | $1,853,000 | $5,231,000 | $8,442,000 |
| Total Capitalization | $158,403,000 | $287,064,000 | $469,076,000 | $-446,850,000 |
| Additional Paid In Capital | $1,288,003,000 | $1,234,207,000 | $1,172,570,000 | $21,430,000 |
| Capital Stock | $17,000 | $16,000 | $16,000 | $3,000 |
| Common Stock | $17,000 | $16,000 | $16,000 | $3,000 |
| Long Term Capital Lease Obligation | $193,000 | $0 | $1,853,000 | $5,072,000 |
| Current Capital Lease Obligation | $284,000 | $1,853,000 | $3,378,000 | $3,370,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,494,000 | $9,975,000 | $10,011,000 | $8,400,000 |
| Current Accrued Expenses | $17,294,000 | $14,618,000 | $11,246,000 | $3,136,000 |
| Net PPE | $457,000 | $2,917,000 | $6,858,000 | $10,642,000 |
| Accumulated Depreciation | $-187,000 | $-2,049,000 | $-1,435,000 | $-1,060,000 |
| Gross PPE | $644,000 | $4,966,000 | $8,293,000 | $11,702,000 |
| Construction In Progress | $0 | $0 | $41,000 | $514,000 |
| Other Properties | $417,000 | $4,621,000 | $7,868,000 | $10,615,000 |
| Machinery Furniture Equipment | $227,000 | $345,000 | $384,000 | $556,000 |
| Other Short Term Investments | $0 | $165,430,000 | $79,944,000 | $130,941,000 |
| Investments And Advances | - | $0 | $9,845,000 | $23,511,000 |
| Leases | - | - | $0 | $17,000 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-206,440,000 | $-182,936,000 | $-163,395,000 | $-115,407,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-206,440,000 | $-182,936,000 | $-163,278,000 | $-114,896,000 |
| Cash Flow From Continuing Operating Activities | $-206,440,000 | $-182,936,000 | $-163,278,000 | $-114,896,000 |
| Operating Gains Losses | $47,000 | - | - | $-559,000 |
| Investing Activities | ||||
| Investing Cash Flow | $168,520,000 | $-70,557,000 | $64,387,000 | $-168,013,000 |
| Cash Flow From Continuing Investing Activities | $168,520,000 | $-70,557,000 | $64,387,000 | $-168,013,000 |
| Net Other Investing Changes | - | $-775,000 | $-4,590,000 | $-13,000,000 |
| Capital Expenditure | - | - | $-117,000 | $-511,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $19,653,000 | $13,694,000 | $233,375,000 | $112,216,000 |
| Financing Cash Flow | $77,089,000 | $21,603,000 | $231,936,000 | $115,743,000 |
| Cash Flow From Continuing Financing Activities | $77,089,000 | $21,603,000 | $231,936,000 | $115,743,000 |
| Net Common Stock Issuance | $19,653,000 | $13,694,000 | $232,884,000 | $0 |
| Common Stock Issuance | $19,653,000 | $13,694,000 | $233,375,000 | $0 |
| Repurchase Of Capital Stock | - | $0 | $-491,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $0 | $112,216,000 |
| Preferred Stock Issuance | - | $0 | $0 | $112,216,000 |
| Net Other Financing Charges | - | - | $-3,804,000 | $-744,000 |
| Other | ||||
| Issuance Of Debt | $57,161,000 | $0 | - | - |
| Interest Paid Supplemental Data | $1,501,000 | $0 | - | - |
| Income Tax Paid Supplemental Data | $323,000 | $473,000 | - | - |
| End Cash Position | $182,530,000 | $143,361,000 | $375,251,000 | $242,206,000 |
| Beginning Cash Position | $143,361,000 | $375,251,000 | $242,206,000 | $409,372,000 |
| Changes In Cash | $39,169,000 | $-231,890,000 | $133,045,000 | $-167,166,000 |
| Proceeds From Stock Option Exercised | $275,000 | $7,909,000 | $2,856,000 | $4,271,000 |
| Net Issuance Payments Of Debt | $57,161,000 | $0 | - | - |
| Net Long Term Debt Issuance | $57,161,000 | $0 | - | - |
| Long Term Debt Issuance | $57,161,000 | $0 | - | - |
| Net Investment Purchase And Sale | $168,302,000 | $-69,782,000 | $69,094,000 | $-154,502,000 |
| Sale Of Investment | $251,170,000 | $242,441,000 | $178,166,000 | $71,867,000 |
| Purchase Of Investment | $-82,868,000 | $-312,223,000 | $-109,072,000 | $-226,369,000 |
| Net PPE Purchase And Sale | $218,000 | $0 | $-117,000 | $-511,000 |
| Sale Of PPE | $218,000 | $0 | - | - |
| Change In Working Capital | $-437,000 | $22,636,000 | $-8,899,000 | $-6,948,000 |
| Change In Other Current Liabilities | $-1,880,000 | $-3,378,000 | $-3,403,000 | $-1,826,000 |
| Change In Other Current Assets | $-53,000 | $0 | $0 | $1,373,000 |
| Change In Payables And Accrued Expense | $4,266,000 | $10,109,000 | $5,905,000 | $-2,867,000 |
| Change In Accrued Expense | $4,195,000 | $7,236,000 | $6,486,000 | $-1,621,000 |
| Change In Payable | $71,000 | $2,873,000 | $-581,000 | $-1,246,000 |
| Change In Account Payable | $71,000 | $2,873,000 | $-581,000 | $-1,246,000 |
| Change In Prepaid Assets | $-2,770,000 | $15,905,000 | $-11,401,000 | $-3,628,000 |
| Other Non Cash Items | $3,133,000 | $3,313,000 | $67,379,000 | $15,331,000 |
| Stock Based Compensation | $29,876,000 | $39,990,000 | $17,240,000 | $8,298,000 |
| Asset Impairment Charge | $595,000 | $0 | - | - |
| Amortization Of Securities | $-2,934,000 | $-5,719,000 | $-3,741,000 | $-708,000 |
| Depreciation Amortization Depletion | $208,000 | $631,000 | $668,000 | $594,000 |
| Depreciation And Amortization | $208,000 | $631,000 | $668,000 | $594,000 |
| Gain Loss On Sale Of PPE | $47,000 | $0 | - | - |
| Net Income From Continuing Operations | $-236,928,000 | $-243,787,000 | $-235,925,000 | $-130,904,000 |
| Common Stock Payments | - | $0 | $-491,000 | $0 |
| Purchase Of PPE | - | $0 | $-117,000 | $-511,000 |
| Gain Loss On Investment Securities | - | - | - | $-559,000 |
| Unrealized Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-19